* Beigene Receives Approval To Initiate Clinical Trials In
China With Pd-1 antibody bgb-a317
The post BRIEF-BeiGene receives approval to initiate clinical trials in China with PD-1 antibody BGB-A317 appeared first on NASDAQ.
BRIEF-BeiGene receives approval to initiate clinical trials in China with PD-1 antibody BGB-A317
